174 related articles for article (PubMed ID: 9629874)
1. Delayed emesis following anticancer chemotherapy.
Kris MG; Roila F; De Mulder PH; Marty M
Support Care Cancer; 1998 May; 6(3):228-32. PubMed ID: 9629874
[TBL] [Abstract][Full Text] [Related]
2. Management of cisplatin-induced delayed emesis.
Hesketh P
Oncology; 1996 Jun; 53 Suppl 1():73-7. PubMed ID: 8692555
[TBL] [Abstract][Full Text] [Related]
3. [The control of chemotherapy-induced nausea and vomiting].
Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
[TBL] [Abstract][Full Text] [Related]
4. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.
Hesketh PJ; Gralla RJ; du Bois A; Tonato M
Support Care Cancer; 1998 May; 6(3):221-7. PubMed ID: 9629873
[TBL] [Abstract][Full Text] [Related]
5. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.
Kris MG; Gralla RJ; Clark RA; Tyson LB; O'Connell JP; Wertheim MS; Kelsen DP
J Clin Oncol; 1985 Oct; 3(10):1379-84. PubMed ID: 4045527
[TBL] [Abstract][Full Text] [Related]
6. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
7. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
9. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
13. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
[TBL] [Abstract][Full Text] [Related]
14. A multivariate analysis for predicting cisplatin-induced delayed emesis.
Pivot X; Marghali N; Etienne MC; Bensadoun RJ; Thyss A; Otto J; François E; Renée N; Lagrange JL; Schneider M; Milano G
Oncol Rep; 2000; 7(3):515-9. PubMed ID: 10767361
[TBL] [Abstract][Full Text] [Related]
15. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
16. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
17. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
19. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
20. [Recent advances in the management of chemotherapy-induced emesis].
Murakami M; Ota K
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):401-11. PubMed ID: 3006594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]